Eli Lilly’s Guidance Raise Changes the Earnings Debate
- Eli Lilly reported third-quarter 2026 earnings and revenue above estimates and raised its full-year sales outlook to $91-$92 billion from $85-$87 billion.
- Mounjaro and Zepbound both exceeded the product-level expectations supplied by StreetAccount, showing that prescription volume can offset lower realized prices.
- The counterweight is Foundayo: its $184 million in third-quarter 2026 sales fell below the cited analyst forecast of about $229 million.
Eli Lilly’s third-quarter 2026 report shifts the investor question from whether obesity and diabetes demand is strong to how efficiently that demand converts into revenue and earnings under falling realized prices. CNBC reported on 2026-10-29 that the company beat earnings and revenue estimates, raised its full-year sales outlook and saw its shares rise about 4% in premarket trading.
GLP-1 drugs are treatments represented here by Mounjaro, Zepbound and Foundayo, with Eli Lilly citing expanded U.S. obesity-care coverage that included Medicare coverage for weight-loss use under a temporary pilot program. For investors, the evidence is positive because demand, market share and guidance moved in the same direction; the report also shows that volume rather than pricing is carrying more of the commercial burden.
Mounjaro and Zepbound Supply the Revenue Engine
Mounjaro worldwide revenue rose 65% to $10.72 billion in the third quarter of 2026, according to CNBC, exceeding StreetAccount’s $10.10 billion expectation. U.S. Mounjaro sales were about $5 billion, also above the $4.79 billion expectation, while sales outside the U.S. increased 93%.
Zepbound generated $5.35 billion in third-quarter 2026 revenue, up 49% from the year-earlier period. StreetAccount had expected $5.09 billion globally and $4.99 billion in the U.S., making the product-level beat broad enough to support the raised company outlook rather than relying on a single geography.
The mix matters. Mounjaro’s international growth gives Eli Lilly a second demand channel beyond the U.S., while Zepbound remains weighted heavily toward U.S. sales. If one market faces greater pricing pressure, geographic and product diversification may cushion revenue, though the supplied evidence does not quantify how much protection that mix provides.
Volume Is Winning the Race Against Lower Prices
Eli Lilly’s U.S. revenue increased 34% to $15.1 billion in the third quarter of 2026. Product volume rose 41%, primarily for Mounjaro and Zepbound, while realized prices declined 7%. That spread is the quarter’s central operating signal: more prescriptions or units sold outweighed the revenue drag from lower pricing.
The same pattern was sharper outside the U.S. Eli Lilly reported a 47% increase in third-quarter 2026 sales outside the U.S. to $9.3 billion, supported by 76% volume growth and partly offset by a 29% decline in realized prices. This creates a demanding checkpoint for future earnings: volume must remain sufficiently strong if realized-price declines persist.
A $410 million third-quarter 2026 sales-based milestone payout for Jardiance, related to Eli Lilly’s collaboration with Boehringer Ingelheim, also supported the quarter. Investors should separate that contribution from the recurring demand signal in Mounjaro and Zepbound when judging the durability of the reported performance.
Market Share Strengthens Lilly’s Position Against Novo
Eli Lilly reported a 63% share of the U.S. obesity and diabetes drug market in the third quarter of 2026, compared with 36.6% for Novo, which Lilly described as its chief rival. Internationally, Lilly’s share was 58.4%, against Novo’s 41.6%.
Those figures frame the competitive position more precisely than broad claims about demand. Lilly led the disclosed share measures in both markets, and its international Mounjaro performance indicates that the revenue opportunity is not confined to the U.S. The next company report should show whether those shares hold as pricing and product competition continue to shape the market.
Foundayo complicates the leadership narrative. The obesity pill recorded $184 million in third-quarter 2026 sales, below the roughly $229 million analyst forecast cited in the source. Its shortfall does not erase the strength of the injectable portfolio, but it means Lilly has not yet demonstrated the same expectation-beating performance across every obesity product.
Higher Sales Guidance Meets a More Complex Earnings Outlook
Eli Lilly now expects $91-$92 billion in 2026 full-year revenue, up from its previous $85-$87 billion range. The revised outlook is the clearest management signal that the product-level momentum is meaningful at the company level, although the source does not provide a precise full-year sales figure within that range.
Adjusted earnings guidance moved to $35-$36 per share from $35.50-$36.50 per share. Lilly said underlying profit guidance increased by $4.07 per share at the midpoint, offset by $4.57 per share in third-quarter 2026 charges tied to deals. The distinction matters because stronger operating expectations and transaction-related charges point in opposite directions within the reported earnings range.
Third-quarter 2026 net income was $6.45 billion, or $7.22 per share, compared with $5.58 billion, or $6.21 per share, in the year-earlier quarter. Excluding specified adjustments, Eli Lilly reported $7.48 per share in adjusted earnings. The supplied evidence says total quarterly earnings and revenue exceeded estimates, though it does not provide complete consensus figures for either measure.
Beneficiaries, Competitive Pressure and Strategic Spending
- Eli Lilly: Higher sales guidance, above-expectation Mounjaro and Zepbound revenue, and leading disclosed market shares support the positive read-through. Lower realized prices and deal charges limit how directly revenue momentum reaches per-share earnings.
- Novo: The disclosed third-quarter 2026 shares place the rival behind Lilly in both the U.S. and international obesity and diabetes drug markets. The fact sheet does not provide Novo revenue, earnings or guidance, so the read-through should remain limited to competitive positioning.
- Merida Biosciences: Eli Lilly struck an agreement to buy the company as part of its activity in treatments for serious autoimmune and allergic diseases. The transaction value and closing date were not provided, preventing a financial assessment of the agreement.
- Boehringer Ingelheim collaboration: The Jardiance relationship produced a $410 million sales-based milestone payout for Eli Lilly in the third quarter of 2026, adding a distinct contribution outside the main obesity-drug figures.
The Checkpoints After Eli Lilly’s Third Quarter
- Guidance conversion: Compare Eli Lilly’s next reported outlook with the current $91-$92 billion 2026 sales range and $35-$36 per-share adjusted earnings range.
- Price-volume balance: Track whether product volume can continue to outrun the 7% U.S. and 29% international declines in realized prices reported for the third quarter of 2026.
- Product breadth: Test whether Foundayo closes the gap between its $184 million quarterly sales and the cited forecast of about $229 million, rather than assuming strength in Mounjaro and Zepbound transfers automatically.
- Competitive position: Recheck Eli Lilly’s U.S. and international market shares against Novo at the next disclosure, since share retention is the cleanest available measure of relative demand.
Bottom Line: Demand Is Proven, Pricing Is the Live Risk
Eli Lilly delivered the combination equity investors typically seek from a pharmaceutical earnings report: above-estimate results, stronger full-year sales guidance and product revenue that surpassed cited expectations. Mounjaro’s $10.72 billion and Zepbound’s $5.35 billion in third-quarter 2026 revenue establish the demand case, while the 4% premarket move indicates a positive initial stock reaction.
The evidence also sets a higher standard for the next report. Falling realized prices, Foundayo’s forecast miss and deal-related charges make volume growth, product breadth and earnings conversion the decisive measures. If Lilly preserves market share and keeps volume ahead of pricing pressure, the raised outlook gains credibility; if that spread narrows, headline demand may translate less efficiently into per-share results.
Market data check: Eli Lilly and Company
Eli Lilly and Company last traded near $1,386.59 (+7.63%). Our composite signal — blending price momentum and news flow — reads 🟡 neutral. Price momentum scores 95/100 (firm).
Data as of publication. Price via market feeds; for reference only, not investment advice.
📊 Analysis
Signal Bullish
Why Above-estimate quarterly results, stronger product demand and higher full-year sales guidance outweigh pricing pressure and Foundayo's forecast shortfall.
This article was independently written by OneDayTrading from public reporting. Read the original (CNBC)
